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1.  Introduction 
 
The communication of cells with one another is absolutely necessary in order to 
coordinate their behavior for the benefit of the organism as a whole.  Complex 
machinery in a cell interprets intercellular signals, enabling it to determine its’ 
position and specialized role, for example that each cell only divides when its 
neighbor tells it to do so.  As new powerful techniques become available to study 
cells, the intricacy and importance of these controls becomes apparent, especially 
when they fail, resulting in cancer. 
The Ras proteins, H-, N-, and K-Ras, members of the superfamily of small GTP-
binding proteins (also called GTPases because of the GTP hydrolysis that they also 
catalyze), play a central role in the regulation of cell growth and differentiation.  They 
are signaling proteins involved in the communication between cells as between 
different cellular compartments.  Mutations in the Ras gene disrupt this delicate 
control and lead to cell proliferation.  As in the case for many other signaling 
molecules, Ras´ activity is dependent on its lipidation state:  lipidated, thus membrane 
bound, Ras is active.  A better understanding of Ras´ function can potentially lead to 
new therapeutic treatments. 
Along with biochemical methods, synthetic organic chemistry has become a helpful 
tool towards the understanding of these mechanisms.  Small, well-defined molecules 
allow the observation of biological events on a molecular scale.  Using lipidated 
peptides, structural information on membrane binding can be gained.  For example, it 
is now possible with 1H high resolution magic angle spinning NMR (1H HR MAS 
NMR) to probe residues’ membrane penetration depth or with deuterium NMR, the 
membrane mobility of peptides [40].  The chemical synthesis of isotopically and non-
isotopically labeled lipidat-modified N-Ras C-terminus peptides for that purpose is 
the object of the presented work. 
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2.  General background 
 
2.1 Protein anchoring through lipidation 
 
Membrane association is essential for the proper cellular distribution and functioning 
of many cell signaling proteins.  Membrane localization and binding is achieved 
through co- and post-translational lipidation of amino acids at or near the N- or C-
terminus of the protein.  In contrast to the permanency of transmembrane binding 
through α-helices and β-barrels, lipidation offers an alternative, reversible binding 
modus.  This reversibility permits the cell to regulate protein functions that only occur 
when the protein is membrane associated. 
Stable membrane insertion requires the presence of at least two lipid groups or one 
lipid group and an attractive electrostatic peptide-membrane interaction [1, 2]. 
Four classes of lipids are found covalently attached to proteins (Fig. 2.1): (1) 
isoprenoid groups such as farnesyl and geranylgeranyl residues, (2) fatty acyl groups 
such as myristoyl and palmitoyl, (3) glycoinositol phospholipids (GPIs), and 
cholesterol. 
Isoprenoid (or prenyl) 1, 2, moieties are attached to a cysteine via a thioether linkage.  
A common prenylation recognition sequence in proteins is the C-terminus  -CaaX 
sequence, also known as –CaaX box, where C is cysteine and a can be any aliphatic 
amino acid.  Although X may be any amino acid, its identity is a major prenylation 
determinant:  when X is either alanine, methionine or serine, the protein is 
farnesylated.  It is geranylgeranylated when X is leucine.  Following prenylation, the 
aaX tripeptide is proteolytically excised and the newly exposed carboxy-group is 
methylated.   
Other prenylation recognition sequences have been characterized and are 
predominantly found in the Ras-related Rab-family of GTPases:  for the -CXC motif, 
both cysteine residues are geranylgeranylated and the C-terminus is then methylated 
[3], whereas  for the –CC- and CCXX motives, one or both cysteines are 
geranylgeranylated but the carboxy-group is not methylated [4]. 
Protein prenylation has been viewed as a mechanism for post-translational 
attachement of proteins to the membrane. It is however becoming increasingly clear 
that prenylation does more than mediate non-specific modified protein association 
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with lipid bilayer.  There is mounting evidence that prenylation plays a specific role in 
protein-protein interactions[5] including those that facilitate protein trafficking[6, 7] 
























S-farnesyl cysteine methyl ester, 1
S-geranylgeranyl cysteine methyl ester, 2










Figure 2.1: Various lipid classes. 
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The C14 myristoyl-group 4 is stably attached as an amide to a proteins’ N-terminal 
glycine.  This modification almost always occurs co-translationally [8]. 
The palmitoyl group, a common C16 fatty acid chain, is post-translationally bound to 
the protein via a cysteine thioester linkage 4[9].  In contrast to other lipid 
modifications, palmitoylation is reversible under physiological conditions.  This 
reversibility may be particularly important for modulating protein function during 
cycles of activation and deactivation.  Palmitoylation can affect the affinity of 
proteins for membranes, subcellular localization and interaction with other proteins 
[10].  Similarly to prenyl moieties, palmitoylated groups are thought to function as 
membrane anchors.  [1, 2, 9]. 
The biological relevance of lipid-modified proteins is highlighted by the role that Ras 
proteins play in maintaining the regular life cycle of cells. 
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2.2 The Ras proteins 
 
The Ras genes produce a family of highly related proteins, the H-, N-, and K-Ras 
proteins which are differentiated from each other by the last 25 C-terminal amino acid 
residues (Fig. 2.2). 
 
Q H K L R K L N P P D E S G P G C M S C K   C V L S
Q Y R M K K L N S S D D G T Q G C M G L P C V V M
Q Y R L K K I S K E E K T P G C V  K  I K  K  C I I M











Figure 2.2:The variable domain of human Ras proteins.  Indicated are the lipidation 
sites. 
 
All Ras proteins are low molecular weight (21kD) GTP hydrolyzing proteins 
(GTPases) which cycle between an inactive GDP-bound state and an active GTP-
bound state.  Because the switch-on and switch-off rates are very slow, the process 
needs to be aided by guanine nucleotide exchange factors (GEFs) and GTPase 
activating proteins (GAPs).  In its inactive state, Ras binds to GDP.  Ras activation by 
GEF catalyzes the dissociation of GDP, facilitating the loading of GTP.  Only in this 
active state can Ras interact with effectors: proteins that interact specifically with the 
GTP-bound state and transmit a signal through, for example, phosphorylation (Fig. 
2.3). 
The signaling is terminated by the GAP-aided GTPase reaction of Ras.  An artificially 
extended lifetime of the signal due to an extended GTP-bound active state, coming for 
example from a point mutation, whose biochemical consequence is to render the 
protein unable to hydrolyze GTP [11], may lead to unregulated biological responses, 
such as uncontrolled cell proliferation, thereafter to cancer.  Activating Ras mutations 
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are particularly associated with myeloid malignancies and carcinomas of the colon, 



























Figure 2.3:  Schematic representation of Ras regulation and function. 
 
Lipidation plays a crucial role in Ras´ activity:  unlipidated, Ras is cytosolic and 
cannot transduce signals [13-15].  All the targeting information is contained in the 
variable domain of the Ras protein.  Covalently attached farnesyl and palmitoyl 




2.3 Biophysical investigation of the membrane insertion of Ras 
 
Although the three dimensional structure of truncated H-Ras protein has been 
determined (residues 1-166 or 1-171)[16-19] and crystals of the full length protein 
have been reported[19], the structure of full length proteins has not yet been solved.  
More precisely, these studies were undertaken in the absence of the C-terminus, 
therefore, the structure dynamics and details of membrane association of the 
membrane binding C-terminus remain unknown. 
Unlike for soluble peptides and proteins, there are few standard techniques available 
for the study of lipid modified peptides to model membranes.  Even if neutron 
diffraction allows the determination of the location of a peptide in a membrane, the 
rarity of a neutron source limits the use of this technique.  While 1H NMR has become 
a standard method to obtain high resolution molecular structures of peptides and 
proteins, it fails for membrane bound peptides because the samples are too large to 
tumble with a short enough correlation time to yield narrow and well-resolved 
resonance lines, as required for high resolution NMR.  The 1H NMR linewidths are 
homogenously broadened typically by several kHz due to strong anisotropic 1H-1H 
dipolar couplings (Fig. 2.4, top).   
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Figure 2.4:  Comparison of MAS and non-MAS spun N-ras peptide in DMPC-d67 
multilamellar liposomes.  The broad, featureless top spectrum corresponds to the 
sample measured without MAS, the bottom spectrum is taken with MAS.[31] 
 
By making use of the 1 - 3cos2 θ dependence of both the dipole-dipole and anisotropy 
and spinning the sample at θ = 54.7o to the applied magnetic field (whereby 1 - 3cos2 
θ = 0), it is possible to average out all dipolar interactions and anisotropies.   
This method has already been shown to be effective for obtaining almost solution-like 
spectra for pure lipid membrane systems[20] and used to study the structure and 
dynamics of these systems[21-25].  Unfortunately, membrane bound peptides only 
reorient themselves slowly, which broadens the NMR lines.  This problem can be 
overcome by spinning the samples at very high speeds (10 to 15 kHz).  Recently, 
Huster et al. showed that 1H HR MAS NMR of bilayer bound lipidopeptides provide 
excellent spectral resolution for structural investigations (Fig. 2.5)[31].  Using the 
unlabelled lipid-modified C-terminus of the N-ras peptide, it was possible to estimate 
the location of the peptide backbone and the lipid side-chains.   
The full assignment, quantitative analysis and dynamics of the peptide location and 
structure are only possible by using N-ras peptides that have been isotopically labeled 
either in the lipid side-chains, or within the backbone itself.  The opportunity that 1H 
HR MAS NMR offers to providing more insight into the mechanism of protein 
insertion into membranes by studying peptides in membrane bilayers could not be 
fully taken advantage of without possessing the know-how for the synthesis of 




Figure 2.5:  600 MHz 1H HR MAS NMR spectrum of the N-ras peptide in DMPC-
d67 multilamellar liposomes at spinning speed 12 kHz.  The peaks labeled G 







2.4 The chemical synthesis of lipidated peptides 
 
2.3.1 Coupling reagents and methods 
 
The reaction coupling two amino acids is endergonic and therefore must be activated 
to obtain significant yields.  Current coupling reagents and methods will be presented 
in the following section. 
 
2.3.1.1    The carbodiimide method 
 
The carbodiimide method emerged as one of the first of these methods [26].  The 
carboxy group of an amino-protected amino acid 6 adds to the carbodiimide 7, 
creating an O-acyl urea intermediate 8.  The free amine of a carboxy protected amino 
acid 12 then nucleophilically attacks this intermediate, forming a new peptide bond 13 
and a urea-derivative 10.  The reactive O-acyl urea intermediate can also rearrange to 
an unreactive N-acyl urea derivative 9.  Addition of a nucleophile, such as N-
hydroxybenzotriazol (HOBt, 17) or 1-hydroxy-7-azabenzotriazole (HOAt, 18), leads 
not only to the formation of an ultra reactive species, which reacts, in the presence of 
a free amine, to form an amide bond, but also raises the acidity of the solution, 
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Figure 2.6:  The mechanism of the carbodiimide mediated coupling. 
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Figure 2.7:  Various carbodiimides and benzotriazoles. 
 
Couplings with N, N´-dicyclohexylcarboiimide (DCC, 14) generate insoluble, 
difficult to remove urea by-products. Alternatively, N, N´-diisopropylcarboiimide 
(DIC, 15)  and N´-(3-dimethylamino-propyl)-N-ethylcarboiimide (EDC, 16) induced 
couplings circumvent this problem by generating  soluble ureas, the latter being 
water-soluble thus easily removable by mild acidic workup. 
 
2.3.1.2  The mixed anhydride method 
 
Amino acids are also efficiently activated by forming a mixed anhydride with 2-
ethoxy-1-ethoxycarbonyl-1,2-dihydrochinoline (EEDQ, 18)[27].  Upon reaction with 
the amino acid 11, the chinoline looses ethanol, forming intermediate 19, which 
undergoes a rearrangement, eliminating choline 20 to form the mixed anhydride 21.  
The free amino group of a carboxy protected amino acid 16 can then nucleophilically 






































Figure 2.8:  The mechanism of the EEDQ mediated coupling. 
 
2.3.1.3  Methods involving phosphonium and uronium reagents 
 
The phosphonium reagent benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium 
hexafluorophosphate (BOP, 23) was introduced in 1988[28] as a highly selective 









































Figure 2.9:  The mechanism of the BOP mediated coupling. 
 
After deprotonation of the amino acid 6 by a tertiary amine, the resulting carboxylate 
anion nucleophilically attacks the phosphorous atom of BOP 23.  The formed 
intermediate 24 is further attacked by the benzotriazole forming the active ester 25, 
which then reacts to form a peptide bond with the free amine of an amino acid.  Due 
to the fact that one of the byproducts of this reaction, hexamethyl triamide phosphoric 
acid (HMPTA) is carcinogenic, reagents such as benzotriazole-1-yl-oxy-tris-
pyrrolidino-phosphonium hexafluorophosphate (PyBOP, 26), 2-(1H-benzotriazole-1-
yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU, 27) were developed.   
An even more reactive coupling reagent has also been developed:  O-(7-



















HBTU, 27 HATU, 28PyBOP, 26  
 
Figure 2.10:  Commonly used benzotriazole coupling reagents. 
 
2.3.2  Solid phase peptide synthesis 
 
Merrifeld’s successful synthesis of the nonapeptide bradykinin in 1964[29] marked 
the beginning of the solid phase peptide synthesis (SPPS) era. 
The concept of SPPS is quite simple: synthesis is conducted in the C- to N-direction.  
The first amino acid is anchored to an insoluble polymer support by means of a 
flexible selectively cleavable linker group.  The peptide chain is elongated through 
repetitive cycles of N-terminus deprotection and coupling.  All soluble reagents are 
filtered away after each step.  At the end of the synthesis, the peptide is selectively 
cleaved from the polymer support.  The repetitive nature of SPPS lends itself ideally 
to automation.  Furthermore, the large excess of reagents used ensures that the 
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reactions go to completion.  This implies that for a synthesis of 100 steps, each step 
yielding 99% yield, one would obtain an overall yield of 36%.  This yield would be 
entirely hopeless to achieve in solution.   
 
2.4 Protecting groups in chemical peptide synthesis 
 
Unambiguous formation of a peptide bond between two structurally similar amino 
acids requires that the amino group of one and the carboxy- group of the other are 
protected.  It is equally important to protect the chemically reactive side chains of 
amino acids. 
Protecting groups must be easily introduced, reduce the reactivity of amino or 
carboxy groups, be chemically stable under peptide coupling conditions and finally be 
easily removable at the end or intermediate phases of the synthesis, leaving the newly 
created amide link intact. 
Described in the coming section are the deprotection methods of the most commonly 
used amino- and carboxyl- protecting groups. 
 
2.4.1 Amino-protecting groups 
 
Urethane derivatives are suitable for amino protection:  they satisfy the above-
mentioned protecting group requirements and the urethane nitrogen is usually 
chemically inert to peptide synthesis conditions.  Commonly used protecting groups 
are the tert-butyloxy carbonyl (Boc), the fluorenylmethoxycarbonyl (Fmoc) and the 



























Figure 2.11: Commonly used protecting groups in peptide synthesis. 
 
2.4.1.1  The tert-butyloxycarbonyl (Boc) protecting group[30] 
 
The Boc group is introduced onto the amine functionality of the amino acid with 
Boc2O.  It is inert under basic conditions and unaffected by catalytic hydrogenation.  
Its´ acid lability is driven by the relative stability of the cleavage product, the tert-













Figure 2.12:  Cleavage mechanism of the Boc group under acidic conditions. 
 
 
2.4.1.2  The fluorenylmethoxycarbonyl (Fmoc) protecting group.[31] 
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The Fmoc group is inert to acids.  It is usually prepared from the chloroformate or the 
derived hydroxysuccinamide ester and is quickly and cleanly removed by secondary 
amines in DMF.  The Fmoc group owes its base lability to the acidity of the 9-
hydrogen atom of 29 due to the resonance stabilization of the cyclopentadiene anion 
30.  The abstraction of this proton initiates a β-elimination. 
The resulting dibenzofulvene 31 generally reacts further with the basic reagent, 
usually piperidine.  The fluorenyl product, 32, of this last reaction has a strong 
absorbance in the ultraviolet region (λmax 301nm), providing the possibility for 



















Figure 2.13:  Piperidine catalyzed Fmoc deprotection. 
 
2.4.1.3  The allyloxycarbonyl protecting group[32] 
 
 
The allyloxycarbonyl protecting group is stable to acidic and basic conditions.  It is 
introduced by coupling the amino acid with allyl chloroformate under Schotten-
Baumann conditions. 
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The deprotection proceeds through the formation of an η3π allylic intermediate, which 



























Figure 2.14:  Mechanism of Pd(0)-mediated cleavage of N- and C-terminal allylic 
protecting groups with dimethyl barbituric acid. 
 
2.4.2 Carboxy-protecting groups 
 
The carboxy function was initially protected with methyl or ethyl esters though their 
cleavage by aqueous alkaline hydrolysis was sometimes difficult.  Alternative 
protecting groups such as tert-butyl or allyl esters are cleaved under analogous 
conditions (acid treatment or Pd(0) mediated) to the corresponding urethanes used for 
amino protection. 
 
2.4.2.1  The tert-butyl ester protecting group 
 
The tert-butyl ester protecting group is one of only two carboxy protecting group that 
is stable to base hydrolysis.  It is introduced by acid catalyzed esterification with t-
butyl acetate[33].  Acid induced cleavage forms a gaseous byproduct, thus commonly 











Figure 2.15:   Acid catalyzed tert-butyl ester deprotection. 
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2.4.2.2  Allyl ester 
 
Allyl esters are mainly introduced by azeotropic esterification[34].  They are elegantly 
removed under palladium (0) catalyzed allylic substitution by a nucleophile such as 
dimethyl barbituric acid or morpholine[32]. 
The cleavage mechanism is depicted in Figure 14. 
 
2.5 Synthesis of lipopeptides 
 
Farnesylated and palmitoylated peptides are respectively acid and base sensitive thus 
precautions need to be taken in order to undertake their synthesis. 
The isolated double bonds of  isoprenoid residues are prone to attack under acidic 
conditions (Fig. 16)[35].  The Boc and tert-butyl groups are thus unsuitable protecting 






Acid attack addition, potentially rearrangement
 
 
Figure 2.16:  Side reactions of the farnesyl group in the presence of acid. 
 
The palmitoyl group is base and nucleophile sensitive and undergoes N-S-acyl shifts 
(Fig. 17)[36].  It spontaneously hydrolyzes at pH>7[37].  Under basic conditions, it 
runs the risk of undergoing β-elimination after dehydroalanine formation[38].  
Synthesis involving Fmoc protecting groups is unsuitable.  Boc, allyl ester or enzyme 

















Figure 2.17:  Side-reactions of the palmitoyl group. 
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3.  Objectives 
 
 
Membrane-bound lipidated proteins play a central role in cell signaling pathways 
which make them attractive research targets.  As the activity of some of these proteins 
seems to be linked to their lipidation state (and perhaps their localization), it is 
therefore essential to understand how these proteins bind to the membrane.  Already 
proven to be effective tools for Ras localization studies to the plasma membrane[39], 
lipidated  N-Ras peptides, which possess the characteristic lipidation pattern of their 
parent lipidated proteins, can also be used to study their structure and dynamics in a 
model lipid membrane by 1H HR MAS NMR[40].   
The object of this work is to synthesize peptides 33 and 34, hexadecyl modified, 
lipidated C-terminus fragment peptides of the N-Ras protein.  The labile farnesyl 
moiety of the original protein has been substituted for a hexadecyl chain in order to 


















































4.  Results and Discussion: 
 
4.1  Retrosynthetic Analysis of Lipidated Ras Peptides 33 and 34 
 
The modified N-Ras peptide was synthesized according to Kuhn[41].  The peptide 
was modularly built from three building blocks, namely, the PG-Gly-Cys(R)-OH 
dipeptide (35), the central PG-Met-Gly-Leu-Pro-OH (36), and the C-terminal H-
Cys(R)-OMe methyl ester (37).  This synthetic strategy permits the rapid assembly of 
the heptapeptide with different cysteine R side chains. 
 
Gly-Cys(R)-Met-Gly-Leu-Pro-Cys(HD)-OMe
Boc-Gly-Cys(R)-OAll               +               Boc-Met-Gly-Leu-Pro-Cys(HD)-OMe
Boc-Gly-OH     +     (Tos*Cys-OAll)2 Boc-Met-Gly-Leu-Pro-OH     +     H-Cys(R)-OMe
Amino Acids Amino Acids Amino Acid  
 
Figure 4.1:  Retrosynthetic strategy for the N-Ras lipidated peptide. 
 
4.2  Synthesis of the unlabelled N-Ras Heptapeptide 
 
4.2.1  Synthesis of lipidated building blocks 
4.2.1.1  Synthesis of HD-X and H-Cys(HD)OMe 
 
The synthesis of hexadecylated building block (37) following the method described 
by Xue et al.[42] gave the desired product in unacceptable yields of 23-26%.  The 
yields were substantially increased to 75% by improving the work-up procedures and 
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by using the more reactive hexadecyl iodide instead of hexadecyl bromide.  The 
literature described workup procedure involves evaporation of the solvent, and the  
resulting crude oil be brought up in an 1N HCl solution followed by product 
extraction in dichloromethane.  Instead of bringing up the crude oil in acid, bringing it 
up in NaHCO3 dramatically increases the yield: non-ionic, it is easier to extract out of 















Figure 4.2:  Synthesis of hexadecylated Cysteine building block 37. 
 
4.2.1.2 Synthesis of lipidated dipeptide Boc-Gly-Cys(R)-OH 
 
To prevent S-N-acyl shift of the palmitoyl group during the synthesis, the 
palmitoylated building block needs to be synthesized as a dipeptide: 35.  The coupling 
of Boc-Gly-OH with (Tos*Cys-OAll)2  was first tried, without success, with EDC as 
coupling reagent.  38 was synthesized from the coupling of Boc-Gly-OH and 
(Tos*Cys-OAll)2 with EEDQ.  After reducing the resulting disulfide dimer with DTT, 
palmitoylation was carried out.  Palladium(0) catalyzed cleavage of the allyl 














































Figure 4.3:  Synthesis of the lipidated dipeptides 35 and 40. 
 
The corresponding hexadecylated building block was produced in a similar manner, 
yielding 40 in 30% yield. 
 
 
4.2.2  Synthesis of PG-Met-Gly-Leu-Pro-OH (36) 
 
The core tetrapeptide Fmoc-Met-Gly-Leu-Pro-OH (42) was initially rapidly 
assembled on solid support using the 2-chlorotrityl resin, HBTU/HOBt coupling 

































Figure 4.4:  Solid phase synthesis of Fmoc-Met-Gly-Leu-Pro-OH, 42. 
 
Although rapid, the solid phase synthesis of the tetrapeptide in large quantities is not 
economically advantageous.  In solution, Boc-Met-Gly-Leu-Pro-OH (43) was 
synthesized from the coupling of Boc-Met-Gly-OH 44 and TFA*H-Leu-Pro-OAll 45.  
Boc-Met-Gly-OH was synthesized by first forming the hydroxysuccinimide active 
ester, and then reacting it with glycine.  The H-Leu-Pro-OAll building block was 
assembled by first coupling Boc-Leu-OH with Tos*H-Pro-OAll using the EEDQ 










1.  DCC, HOSu
2.  Gly, Na2CO3, 




























Figure 4.5:  Synthesis of tetrapeptide Boc-Met-Gly-Leu-Pro-OH, 43. 
 
4.2.3  Assembly of lipidated peptide 33 
 
Tetrapeptide 42 is first coupled to hexadecylated 37 with standard EDC methodology.  
After Fmoc deprotection, 47 is coupled to dipeptide 35, generating 48.  Final Boc 
















































































1.EDC, Et3N, CH2Cl2. 54%

















4.3  Synthesis of the Deuterium-Labelled Lipidated N-Ras 
Heptapeptide   
 
4.3.1  Preparation of Labelled Lipidated Building Blocks 
 
4.2.1.1  Synthesis of HD-d33-I (49) 
 
Due to the encouraging yields in the preparation of the unlabeled compounds, it was 
decided to undertake the synthesis of the deuterated hexadecyl cysteine with 
hexadecyl-d33 iodide (49).  As hexadecyl-d33 alcohol, and not hexadecyl-d33 iodide, 
can be purchased, different methods for the efficient transformation of hexadecyl 
alcohol to hexadecyl iodide were probed on unlabelled substrate (Table 1).  The most 
efficient synthesis involved the Appel reaction [43] (PPH3, I2, imidazole), yielding 
hexadecyl iodide in 98% yield. 
 
Product Reagents Yield 
HD-Br PBr5, toluene 24% 
HD-Br MeSO2Cl, pyr, DCM; NaBr, DMSO, ∆ 61% 
HD-Br PPH3, CBr4, DCM 94% 
HD-I CeCl3.H2O, NaI, acetonitrile, ∆ 30% 
HD-I MeSO2Cl, pyr, DCM; NaI, DMSO, ∆ 59% 
HD-I PPh3, imidazole, I2, ether/acetonitrile 98% 
 
Table 1:  Halogenation of hexadecyl alcohol. 
 
The desired hexadecyl-d33 iodide was thus prepared from hexadecan-d33-ol in 85% 
yield using the Appel reaction. 
 
4.2.1.2  Synthesis of H-Cys(HD-d33)-OMe (50) 
 
H-Cys(HD-d33)-OMe (50) was prepared following the optimized procedures worked 
out for the non-labelled building block 37 (Fig. 4.7).  The yields for the deuterated 

















Figure 4.7:  Synthesis of labelled cysteine methyl ester, 50. 
 
4.2.1.2 Synthesis of lipidated dipeptide Boc-Gly-Cys(HD-d33)-OH (51) 
 
Dipeptide 51 was synthesized similarly to the non-labelled substrate (Fig. 4.3) 
























Figure 4.8:  Synthesis of 51. 
 
4.3.2  Peptide Assembly 
The target deuterated N-Ras peptide was assembled in solution analogously to the 














































































1.EDC, Et3N, CH2Cl2 .  63%
2. TFA, thioanisole, CHCl3. 97%












Figure 4.9:  Assembly of 34. 
 33
5. Conclusion and Outlook 
 
The study of the structural and dynamical properties of lipidated peptides and proteins 
to membrane has long been limited by a lack of methods for the synthesis of 
lipopeptides and permitting biophysical techniques.  The synthetic problems have 
been mostly overcome and there now exist new 1H HR MAS NMR methods which 
would make these structural and dynamical studies possible[40].   
The dually lipidated, modified, N-Ras peptide 33 was and will be used as a model 
compound in developing this NMR method.  Dually deuterium-labelled N-Ras 34 will 
also serve useful. 
The modified N-Ras peptide contains a hexadecyl group instead of the original 
farnesyl group to improve the interpretation of the spectra from NMR experiments.  
The deuterated peptide 34 contains two hexadecyl groups instead of one in order to 
















































Figure 5.1:  The target lipidated-modified N-Ras heptapeptides 33 and 34. 
 
 34
The lipid groups were introduced onto dipeptide 38 to prevent possible S-N acyl shifts 













Figure 5.2:  Lipidation of 38. 
 
Due to its’ quicker accessibility, the core tetrapeptide 36 was prepared on 2-











Figure 5.3:  Solid Phase synthesis of Fmoc-Met-Gly-Leu-Pro-OH, 42. 
 
As excess reagents is used in SPPS, it is not a suitable method when the reagents are 
excessively expensive (e.g. when isotopically labeled reagents are required).  For that 











Figure 5.4:  Solution synthesis of core tetrapeptide, 43. 
 
The final assembly steps for the target peptide 33 were carried out in solution using 
standard EDC coupling methods.  After TFA deprotection of the Boc group, the target 




Fmoc-Met-Gly-Leu-Pro-OH   42
Fmoc-Met-Gly-Leu-Pro-Cys(HD)-OMe
1.Boc-Gly-Cys(Pal)-OH,











Figure 5.5:  Assembly of the target heptapeptide, 33. 
 
In preparation for the synthesis of deuterated heptapeptide 34 for deuterium 
membrane dynamics NMR experiments, iodination (Fig 5.7) and hexadecylation 
reactions (Fig. 5.8) were successfully optimized on non-labeled substrate. 
 
As only hexadecyl-d-33-ol is commercially available, hexadecyl-d33 iodide needs to be 
synthesized in order to lipidate H-Cys-OMe.  The best iodination procedure involved 







Figure 5.7:  Iodination of hexadecyl-d33-ol. 
 
The hexadecylation reaction of 37 was undertaken under the same conditions as the 
palmitoylation (Fig. 5.2). 







6.    Experimental section 
 
6.1    Materials and methods 
 
NMR spectroscopy 
The 1H and 13C NMr spectra were recorded on the following instrument: 
400 MHz 1H and 100.6 MHz 13C NMR   Varian Mercury 400 
The chemical shifts were referenced against CHCl3 solvent peak and are given in 
ppm.  The coupling constants J are given in Hz and the multiplicities are abbreviated 
as follows:  s = singlet;  d = doublet;  t = triplet;  m = multiplet. 
 
Mass spectrometry 
The MALDI-TOF spectra were measured on a Voyager-DE Pro BioSpectrometry 
Workstation from PerSeptive Biosystems using 2,5-dihydroxy benzoic acid as matrix. 
 
Optical rotation: 
The optical rotation [α]D20 was measured using a Perkin-Elmer polarimeter 241.  The 
concentrations and solvents used are noted in parenthesis. 
 
Chromatography: 
Thin layer chromatography plates were obtained from Merck (Silica gel 60, F254).  
Tlcs were visualized under UV light (λ = 254 nm, 366 nm).  The tlcs were stained 
using the following stains: 
a) 2.5 g molybdate phosphoric acid, 1 g cerium (IV)-sulfate, 6 ml conc. H2SO4 in 
94 ml H2O. 
b) 0.3 g ninhydrin, 3 ml acetic acid, 100 ml ethanol. 
c) 1.6 g potassium permanganate, 10 g potassium carbonate, 2.5 ml 5% sodium 
hydroxide, 200 ml H2O 
The solvent system and Rf values are noted for all synthesized substances.   





All chemicals were purchased from the following suppliers and used without further 
purification:  Aldrich, Bachem, Fluka, Senn Chemicals. 
 
Solvents 
The solvents were distilled prior to use following standard protocols.[45] 
 
 




Cystin (5 g, 20.8 mmol), p-Tos-OH (15.83 g, 82.22 mmol), allyl alcohol (17 ml, 249.6 
mmol) and 300 ml benzene were combined in a 500 ml round bottom flask equiped 
with a Dean-Stark condensor.  The mixture was heated to 90oC for 16h.  The benzene 
and allyl alcohol were evaporated under reduced pressure.  The product was 
precipitated from the resulting oil with diethyl ether and then dried in vacuo. 
 
White solid. 
Yield:  14.1g (100%). 
 
1H-NMR (400 MHz, MeOD): 
δ = 7.74 (d, J= 8.24Hz, 4H, CH p-Tos-OH), 7.27 (d, J= 8.4Hz, 4H, CH p-Tos-OH), 
6.04 (m, 2H, CH=CH2), 5.45 (dd, 2H, J=17.2Hz, J=, CH=CH2), 5.34 (dd, 2H, 
J=10.36Hz, J=, CH=CH2), 4.80 (m, 4H, OCH2), 4.51 (m, 2H, α-CH Cys), 3.37 (m, 




( (Boc-Gly-Cys-OAll)2)  (38) 
(TosOH.Cys-OAll)2 (2.5 g, 3.75 mmol) was first dissolved in 100 ml of DCM and 20 
ml TFE.  Boc-Gly-OH (1.31 g, 7.7 mmol) was then added.  The solution was then 
cooled to 0oC before EEDQ (2.4 g, 9.75 mmol) and triethylamine (1.04 ml, 7.5 
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mmol) were added.  The reaction was brought up to room temperature overnight.  
After 18h, the reaction organic phase was washed 3 times each with 1N HCl, sat. Sln 
NaHCO3, brine followed by drying over Na2SO4.  The crude oil was purified by flash 
chromatography in 1:1 ethyl acetate/cyclohexane. 
 
Yellow oil. 
Yield:  1.463 g (61 %)  
Rf value:  0.17 (1:1 ethyl acetate/cyclohexane) 
[α]D20:  -51.8o (c = 1.1, MeOH) 
 
1H-NMR (400 MHz, CDCl3): 
δ = 7.16 (m, 2 H, CONH), 5.88 (m, 2 H, CH=CH2), 5.52 (m, 2 H, OCONH), 5.35 (dd, 
J = 17.3 Hz, 3J = 1.56 Hz, 2 H, CH=CH2a), 5.28 (dd, J = 10.56, J = 1.4 Hz, 2 H, 
CH=CH2b), 4.88 (m, 2 H, α-CH Cys), 4.66 (m, 4 H, OCH2), 3.87 (m, 4 H, α-CH2 
Gly), 3.20 (m, 4 H β-CH2 Cys), 1.46 (s, 18 H, C(CH3)3). 
 
13C-NMR (125 MHz, CDCl3): 
δ =169.84 (6*C=O), 131.28 (2* CH=CH2), 119.29 (2* CH=CH2), 66.57 (2* CH2-O, 
Allyl), 52.07 (cys), 41.10 (gly), 28.31 (6* CH3, Boc). 
 
 
N-tert-butyloxycarbonylglycyl-S-palmitoyl-L-cysteine allyl ester 
( Boc-Gly-Cys(Pal)-OAll ) (39) 
DTT (1.36 g, 8.82 mmol) and triethylamine (0.613 ml, 4.4 mmol) were added to a 
degassed solution of (Boc-Gly-Cys-OAll)2 in 50 ml DCM.  After 1.5 hours, the 
reaction was extracted three times with H2O and dried over Na2SO4.  The solvent was 
evaporated under reduced pressure to a colorless oil.  The oil was then dissolved in 10 
ml freshly distilled THF and cooled to 0oC before adding triethylamine (0.754 ml, 
5.41 mmol) and palmitoyl chloride (2.08 ml, 6.86 mmol).  After 2 hours, the reaction 
was filtered over celite, and the solvent was evaporated under reduced pressure.  The 




Yield: 1.21 g (99 %) 
Rf Value:  0.53 (1:1 ethyl acetate/cyclohexane) 
[α]D20:  -14.0o (c = 1.0, MeOH) 
 
1H-NMR (400 MHz, CDCl3): 
δ =5.88 (m, 1H, CH=CH2), 5.34 (dd, 3J = 17.2 Hz, 2J = 1.4 Hz, 2H, CH=CH2a), 5.27 
(dd, 3J = 10.5 Hz, 2J = 1.0 Hz, 1H, CH=CH2b), 4.82 (m, 1H, α-CH Cys), 3.80 (m, 2H, 
α-CH2 Gly, β-CH2 Cys), 2.56 (t, 3J = 7.2 Hz, α-CH2 Pal), 1.60-1.65 (m, 2H, β-CH2 
Cys), 1.46 (s, 9H, C(CH3)3), 1.23 (s, 24 H, (CH2)12 Pal), 0.87 (t, 3J = 6.5 Hz, ω-CH3 
Pal). 
 
13C-NMR (125 MHz, CDCl3): 
δ =169.62 (C=O), 35.28, 31.91, 29.66, 29.65, 29.63, 29.61, 29.57, 29.55, 29.38, 




( Boc-Gly-Cys(Pal)-OH ) (35) 
Boc-Gly-Cys(Pal)-OAll (1.2 g, 2.15 mmol) and DMB (0.673 g, 4.31 mmol) were 
dissolved in 100 ml of freshly distilled THF and the solution was degassed.  After 
addition of palladium triphenyl phosphine tetrakis (50 mg, 0.043 mmol), the reaction 
was stirred in the dark under argon atmosphere for two hours.  The solvent was 
evaporated under reduced pressure, and the crude substance was redissolved in DCM.  
The organic phase was washed three times with 1M HCl, and then dried over Na2SO4.  
After evaporation, the crude solid was purified by flash chromatography first with  1:2 
ethyl acetate/cyclohexane; the product was eluted with 1:7 ethanol/DCM. 
 
Pale yellow solid. 
Yield:  81% 
Rf value: 0.3 (10:1 ethyl acetate/methanol, + 1% vol. acetic acid) 
[α]D20:  -5.0 (c = 1.1, MeOH) 
1H-NMR (400 MHz, CDCl3): 
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δ = 4.37-4.41 (m, 1H, α-CH Cys), 3.84 (d, J = 17 Hz, 1H, α-CH2a Gly), 3.69 (d, J = 
17 Hz, 1H, α-CH2a Gly), 3.42-3.46 (m, 1H, β-CH2 Cys), 2.55 (t, 3J = 7.3 Hz, α-CH2 
Pal), 1.46 (s, 9H, C(CH3)3), 1.24 (s, 24H, (CH2)12 Pal), 0.86 (t, 3J = 6.5 Hz, ω-CH3 
Pal). 
 
S-hexadecyl-L-Cysteine methyl ester 
( H-Cys(HD)-OMe )  (37) 
Diisopropylethylamine (101 µl, 0.582 mmol) and hexadecyl iodide (205 mg, 0.582 
mmol) were added to a stirring solution of Cys-OMe.HCl (50 mg, 0.291 mmol) in 
DMF.  After 18 hours, the solvent was removed under reduced pressure.  The 
remaining solid was brought up in diethyl ether and saturated NaHCO3.  The aqueous 
phase was extracted three times with diethyl ether.  The combined organic phases 
were washed with brine and dried over Na2SO4.  The crude oil was further purified by 
flash chromatography in 1:1 ethyl acetate/cyclohexane. 
 
White solid. 
Yield: 78 mg (75 %) 
Rf value: 0.26 (1:1 ethyl acetate/cyclohexane) 
 
1H-NMR (400 MHz, CDCl3): 
δ = 3.75 (s, 3H, OCH3), 3.68 (m, 1H, α-CH Cys), 2.89 (m, 1H, β-CH2 Cys), 2.51 (t, J 
= 7 Hz, 2H, α-CH2 HD), 1.50 (m, 2H, β-CH2 HD), 1.18 (br s, 26H, (CH2)13 HD), 0.81 
(t, J = 7 Hz, 3H, ω-CH3 HD) 
 
13C-NMR (125 MHz, CDCl3): 
δ =52.73 (α-CH Cys), 34.92 (β-CH2 Cys), 31.91, 31.90, 29.69, 29.65, 29.53, 29.50, 
29.35, 29.22, 28.78 (9* CH2 HD), 22.68 (CH2 HD), 14.10 (ω-CH3 HD). 
 
MALDI-TOF m/z: calc.: 360.61 [M+H]+  found: 360.71 
   calc.: 382.60 [M+Na]+ found: 382.69 
 
 
6.3    Compounds from chapter 4.2.2 
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N-tert-butyloxycarbonylleucyl-L-proline allyl ester 
( Boc-Leu-Pro-OAll ) (45a) 
Boc-leucine (1.36g, 5.0 mmol) and Tos.Pro-Oall (1.93 g, 5.9 mmol) were dissolved in 
100 ml of freshly distilled dichloromethane.  The clear, colorless solution was cooled 
to 0oC before adding triethylamine (0.821 ml, 5.9 mmol) and EEDQ (1.9 g, 7.67 
mmol).  The solution was left to come up to room temperature overnight.  After 16 
hours, the organic phase was extracted twice each with 1M HCl, saturated NaHCO3, 
and then once with brine.  The combined organic phases were dried over Na2SO4 and 
evaporated under reduced pressure.  The crude oil was purified by flash 
chromatography in 1:3 ethyl acetate:cyclohexane. 
 
Colorless oil. 
Yield:  2.06 g (94%). 
Rf value:  0.56 (1:1 ethyl acetate/cyclohexane) 
[α]D20:  -72.5o (c = 1.0, CHCl3) 
 
1H-NMR (400 MHz, CDCl3): 
δ = 5.88 (m, 1H, CH=CH2), 5.33 (dd, J= 17.2Hz, J= 1.4Hz, 1H, CH=CH2a), 5.29 (dd, 
J=10.4Hz, J=4.1Hz, 1H, CH=CH2b), 5.11 (d, J= 9Hz, 1H, OCONH), 4.60 (m, 2H, 
OCH2), 4.54 (m, 1H, α-CH), 4.46 (m, 1H, α-CH), 3.76 (m, 1H, δ-CH2a Leu), 3.59 (m, 
1H, δ-CH2b), 2.21 (m, 1H, β-CH2a Pro), 2.01 (m, 3H, β-CH2b Pro, γ-CH2 Pro), 1.74 
(m, 1H, γ-CH Leu), 1.49 (m, 2H, β-CH2 Leu), 1.41 (s, 9H, C(CH3)3), 0.98 (d, J= 
6.45Hz, 3H, ω-CH3 Leu), 0.94 (d, J= 6.06Hz, 3H, ω-CH3). 
 
13C-NMR (125 MHz, CDCl3): 
δ = 171.6 (3* C=O), 131.78 (CH=CH2), 118.4 (CH=CH2), 79.4 (C(CH3)3), 65.6 (CH2-
O, Allyl), 58.7 (α-CH Pro), 51.2 (α-CH Leu), 46.7(δ-CH Pro), 42.0 (β-CH Leu), 28.9 






L-Leucyl-L-proline allyl ester 
( H-Leu-Pro-OAll ) (45) 
Boc-Pro-Leu-OAll(181 mg) was dissolved in 2 ml chloroform.  The clear, colorless 
solution was cooled to 0oC before adding 2 ml TFA.  After 15 min, the mixture was 
brought up to room temperature and stired for an additional 1.5h.  The TFA and 
chloroform were then co-evaporated with toluene under reduced pressure.   
 
Colorless oil. 
Yield:  0.171 g (91%). 
[α]D20:  -53.6o (c = 1.0 CHCl3). 
 
1H-NMR (400 MHz, CDCl3): 
δ = 5.84 (m, 1H, CH=CH2), 5.27 (dd, 3Jtrans=17.3Hz, 2J= 1.4Hz, 1H, CH=CH2a), 5.22 
(dd, 3Jcis=10.4Hz, 2J=1.1Hz, 1H, CH=CH2b), 4.58 (m, 2H, OCH2), 4.46 (m, 1H, α-
CH), 3.68 (m, 1H, δ-CH2b), 3.48 (m, 1H, δ-CH2b), 2.23 (m, 1H, β-CH2a Pro), 2.02 (m, 
3H, β-CH2b Pro, γ-CH2 Pro), 1.72 (m, 1H, γ-CH Leu), 1.52 (m, 2H, β-CH2 Leu), 0.97 




( Boc-Met-Gly-OH ) (44) 
Boc-Met-OH (2 g, 8.02 mmol) was dissolved in 20 ml of dry THF and cooled to 0oC 
in an ice water bath before adding N-hydroxysuccinimide (0.923 g, 8.02 mmol) and 
dicyclohexyl carbodiimide (1.72 ml, 8.34 mmol).  The mixture was stirred at room 
temperature for 16h after which the dicyclohexyl urea byproduct was filtered away.  
The filtrate was then evaporated under reduced pressure to a white solid, which was 
redissolved in 10 ml dioxane and added to a clear, colorless solution of glycine (0.903 
g, 12.03 mmol) and NaOH (0.320 g, 8.02 mmol) in 40 ml water and 10 ml dioxane.  
The mixture was stirred at room temperature for 3 days before the dioxane was 
evaporated under reduced pressure.  The pH of the remaining aqueous solution was 
adjusted to 8 and then twice extracted with dichloromethane and once with diethyl 
ether.  The aqueous phase was then acidified to pH 2, extracted three times with ethyl 
acetate, affording 5 as a white amorphous solid (2.26 g, 92% yield). 
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White amorphous solid. 
Yield:  2.26 g (92%). 
Rf value:  0.1 (1:1 cyclohexane/ethyl acetate, 1% acetic acid). 
[α]D20:  -16.6o (c = 1.1, MeOH). 
 
1H NMR (400 MHz, MeOD): 
δ =  4.17-4.25 (m, 1H, α-CH2 Met), 3,98 (d, J = 17.5 Hz, 1H, α-CH2a Gly), 3.85 (d, 
J= 17.5 Hz, 1H, α-CH2b Gly), 2.50-2.58 (m, 2H, γ-CH2 Met), 2.09 (s, 3H, SCH3), 
1.98-2.08 (m, 1H, β-CH2a Met), 1.81-1.94 (m, 1H, β-CH2b Met), 1.43 (s, 9H, 
C(CH3)3). 
 
13C (100.6 MHz, MeOD)  




N-tert-butyloxycarbonylmethionylglycyl-L-leucyl-L-proline allyl ester 
( Boc-Met-Gly-Leu-Pro-OAll ) (46) 
Boc-Met-Gly-OH (120 mg, 0.392 mmol) and Leu-Pro-OAll.TFA (150 mg, 0.392 
mmol) were dissolved in DCM in a warm water bath.  EDC (97 mg, 0.509 mmol), 
triethylamine (54.7 µl, 0.392 mmol) and HOBt (90 mg, 0.588 mmol) were added to 
the 0oC cooled slightly yellow colored solution.  The mixture was left to come up to 
room temperature overnight.  After 16h, the organic phase was washed twice each 
with 1M HCl and sat. NaHCO3.  The organic phases were combined and dried over 
Na2SO4 and evaporated under reduced pressure.  The resulting oil was 
chromatographed in straight ethyl acetate. 
 
White solid. 
Yield: 177 mg (81%) 
Rf value:  0.41 (100% ethyl acetate) 
[α]D20:  -36.2o (c = 1.0 CHCl3) 
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1H-NMR (400 MHz, CDCl3): 
δ = 5.85 (m, 1H, CH=CH2), 5.31 (dd, J= 16Hz, J= 1.4Hz, 1H, CH=CH2a), 5.23 (dd, 
J=10.36Hz, J=4.1Hz, 1H, CH=CH2b), 4.77 (m, 1H, α-CH), 4.60  (m, 1H, OCH2), 4.55 
(m, 1H, OCH2), 4.26 (m, 1H, α-CH), 3.99 (m, 1H, α-CH2a Gly), 3.88 (m, 1H, α-CH2b 
Gly), 3.80 (m, 1H, δ-CH2b Pro), 3.60 (m, 1H, δ-CH2a Pro), 2.56 (t, J=7.24Hz, 2H, γ-
CH2 Pro), 2.09 (s, 3H, SCH3), 1.97 (m, 1H, γ-CH Leu), 1.55 (m, 2H, β-CH2 Leu), 
1.43 (s, 9H, C(CH3)3), 0.96 (d, J= 6.64Hz, 3H, ω-CH3 Leu), 0.93 (d, J= 5.67Hz, 3H, 
ω-CH3 Leu). 
 
13C-NMR (125 MHz, CDCl3): 
δ = 171.93, 171.43, 171.24, 169 (4* C=O), 155.68 (OCONH), 131.73 (CH=CH2), 
118.56 (CH=CH2), 79 (C(CH3)3), 65.72 (CH2-O, Allyl), 58.91 (α-CH Pro), 53.54 (α-
CH Met), 49.20 (α-CH Leu), 46.90 (δ-CH Pro), 42.72 (α-CH Gly), 41.43 (β-CH Leu), 
30.18, 30.13 (CH2 Met), 28.97 (β-CH Pro), 28.31 (C(CH3)3), 24.87 (γ-CH2 Pro), 24.56 
(γ-CH2 Leu), 23.26, 21.82 (2* ω-CH3 Leu), 15.30 (SCH3). 
 
N-tert-butyloxycarbonylmethionylglycyl-L-leucyl-L-proline allyl ester 
Boc-Met-Gly-Leu-Pro-OAll 
Boc-Met-Gly-Leu-Pro-OAll and DMB were dissolved in freshly distilled THF and the 
solution was then thoroughly degassed before the addition of palladium 
triphenylphosphine tetrakis.  The clear yellow colored solution was allowed to stir at 




( Fmoc-Met-Gly-Leu-Pro-OH ) (42) 
Amino acid loading proceedure:  the proline loaded resin was prepared from chloro-
chloro tritylchloride resin (1.08 mmol/g), by adding Fmoc proline, dissolved in DCM 
to preswelled resin.  DIPEA was added to the slurry and was shaken for 2.5 hours at 
room temperature.  The unreacted chloride groups were then displaced by the addtion 
of 6 ml MeOH with 1 ml DIPEA, and shaken for another 20 minutes.  The resin was 
then washed 4 times each with DCM, DMF and once more with DCM.  The Fmoc 
group of the resulting loaded resin was promptly removed with 20% piperidine in 
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DMF (20 minutes) in order to quench any possible acid that would result in premature 
cleavage.  
Coupling proceedure:  (repeated 4 times):  the Fmoc group was first removed by 
shaking for 20 minutes 20 ml of a solution of 20% piperidine in DMF.  The resin is 
washed 4 times each with 20 ml DCM and DMF.  The resin was then qualitatively 
tested with the kaiser reagent test to ensure that the N-terminus is free.  The amino 
acids are dissolved in DMF and then preactivated by the addition of HBTU, HOBt 
and DIPEA.  The preactivated amino acid is added to a slurry of resin and shaken for 
2 hours at room temperature, time afterwhich the resin is once again washed 4 times 
each with DCM and DMF.   
Resin cleavage proceedure:  The resin was first preswelled in DCM.  After transfering 
to a round bottom flask, the cleavage cocktail is added (1% TFA, 1% TIS in 10 ml 
DCM).  The slurry is shaken for 1 hour at room temperature, and the resin then 
filtered out.  The filtrate is evaporated and the resulting oil chromatographed in ethyl 
acetate / MeOH (3:2). 
 
Yield: 200 mg (52%). 
Rf value: 0.35 (3:2 ethyl acetate/MeOH) 
[α]D20:  -20.8o (c = 1.1, CHCl3) 
 
1H-NMR (400 MHz, CDCl3): 
δ = 8.04 (d, J= , 1H, CONH), 7.76 (d, J= , 2H, arom. CH), 7.57-7.53 (m, 3H, arom. 
CH, CONH), 7.38 (t, J= , 2H, arom. CH), 7.23 (t, 2H, arom. CH), 5.61 (d, J= 8.0 Hz, 
1H, CONH), 5.00-4.98 (m, 1H, α-CH), 4.40 (m, 4H, 2 * α-CH, OCH2), 4.21 (t, 3J = 
6.0 Hz, 1H, Fmoc), 4.00 (m, 2H, α-CH2 Gly), 3.77 (m, 1H, δ-CH2 Pro), 3.65 (m, 1H, 
δ-CH2 Pro), 2.53 (m, 2H, γ-CH2 Met), 2.35 (m, 1H, β-CH2), 2.08 (m, 2H, β-CH2), 
2.04 (s, 3H, SCH3), 1.97 (m, 3H, β-CH2, γ-CH2 Pro), 1.53 (m, 3H, γ-CH2 Leu, β-CH 
Leu), 0.93 (t, J =  6.44 Hz, 6H, 2*ω-CH3 Leu). 
 
 
13C-NMR (125 MHz, CDCl3): 
δ = 173.63, 172.02, 171.42 (5*C=O), 156.26 (OCONH), 144, 143.85, 141.51 (3* 
arom. Quart. C), 128.32, 127.95, 125.50, 120.20 (4 * arom. CH), 60.63 (α-CH Pro), 
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49.31 (α-CH Leu), 47.90 (δ-CH Pro), 47.36 (Fmoc CH), 43.06 (α-CH2 Gly), 42.78 
(β-CH2 Leu), 31.96, 30.29 (2 * CH2 Met), 29.09 (β-CH2 Pro), 25.34 (γ-CH2 Pro), 
24.64 (γ-CH2 Leu), 23.45, 22.32 (2 * ω-CH3 Leu), 15.52 (SCH3). 
 
MALDI-TOF m/z: calc.: 638.28 [M+Na]+ found: 661.59 
 




( Fmoc-Met-Gly-Leu-Pro-Cys(HD)-OMe )    (47a) 
EDC (39 mg, 0.202 mmol), triethylamine (21.7 µl, 0.156 mmol) and HOBt (36 mg, 
0.234 mmol) were added to a cooled, stirring solution of Fmoc-Met-Gly-Leu-Pro-OH 
(100 mg, 0.156 mmol) and Cys(HD)-OMe (56 mg, 0.156 mmol). The reaction was 
brought up to room temperature overnight.  After 18h, the reaction organic phase was 
extracted two times each with 1N HCl, sat. NaHCO3, brine followed by drying over 
Na2SO4.  The crude oil was purified by flash chromatography in straight ethyl acetate. 
 
Pale yellow solid. 
Yield:  83 mg (54 %) 
Rf value:  0.68 (10:1 ethyl acetate/methanol + 1% vol. acetic acid) 
 
1H-NMR (400 MHz, CDCl3): 
δ = 8.18 (d, J = 5.28 Hz, 1H, CONH), 7.74 (d, J = 7.76 Hz, 2H, arom. CH), 7.57-7.53 
(m, 3H, arom. CH, CONH), 7.38 (t, J = 7.32 Hz, 2H, arom. CH), 7.29 (t, J = 7.48 Hz, 
2H, arom. CH), 6.28-5.85 (br s, 1H, OCONH), 4.93-4.84 (m, 1H, α-CH), 4.63 (m, 
2H, 2 * α-CH), 4.40 (m, 2 H, α-CH, OCH2), 4.20 (m, 1 H, Fmoc CH), 4.09 (m, 2 H, 
α-CH2 Gly), 3.81 (m, 1H, δ-CH2 Pro), 3.71 (s, 3H, OCH3), 3.64 (m, 1H, δ-CH2 Pro), 
2.91 (m, 1H, β-CH2 Cys), 2.81 (m, 1H, β-CH2 Cys), 2.52 (m, 2H, γ-CH2 Met), 2.44 
(m, 2H, β-CH2 Met), 2.21 (m, 2H, CH2 Pro), 2.08 (s, 3H, SCH3), 1.97 (m, 2H, CH2 
Pro), 1.57 (m, 4H, γ-CH2 Leu, β-CH2 Leu), 1.50 (m, 2H,  β-CH2 HD), 1.45 (s, 9H, 
C(CH3)3), 1.24 (s, 24H, (CH2)13 HD), 0.95 (t, 3J = 6.0 Hz, 2 * ω-CH3 Leu), 0.88 (t, 3J 
= 7.0 Hz, 3H, ω-CH3 HD) 
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MALDI-TOF m/z: calc.: 1002.54 [M+Na]+ found: 1002.81 




L-Methionylglycyl-L-leucyl-L-prolyl-S-hexadecyl-L-cysteine methyl ester 
( H-Met-Gly-Leu-Pro-Cys(HD)-OMe )  (47) 
Piperidine (0.5 ml) was added to a solution of Fmoc-Met-Gly-Leu-Pro-Cys(HD)-OMe 
(80 mg, 82µmol) in 2.5 ml chloroform.  After stirring the solution two hours, the 
mixture was first evaporated, and then coevaporated with toluene, and chloroform.  
The crude mixture was purified via flash chromatography first with straight ethyl 
acetate.  The product was then eluted with 7:1 ethyl acetate/methanol. 
 
Yield:  51 mg (80 %) 
Rf value:  0.05 (10:1 ethyl acetate/methanol) 
 
1H-NMR (400 MHz, CDCl3): 
δ = 8.02 (m, 1H), 7.68 (d, J = 7.36 Hz, 1H, CONH), 7.61 (d, J = 8.8 Hz, 1H, CONH), 
4.90-4.80 (m, 1H, α-CH), 4.68-4.56 (m, 1H, α-CH), 4.14-4.02 (m, 2 H), 3.86-3.76 
(m, 1H), 3.70 (s, 3H, OCH3), 3.67-3.54 (m, 1H, δ-CH2b Pro), 2.83 (dd, J = 13.76 Hz, 
J = 7.64 Hz, 2H), 2.58 (t, J = 6.92 Hz, 2H, CH2 Met), 2.42 (t, J = 7.4 Hz, 2H, α-CH2 
HD), 2.07 (s, 3H, SCH3), 2.20-2.00 (m, 6H, β-CH2  Met, β-CH2 Pro, γ-CH2 Pro), 
1.80-1.75 (m, 1H, γ-CH Leu), 1.70-1.60 (m, 4H, β-CH2 Leu, β-CH2 HD); 1.50-1.45 
(m, 2H, CH2 HD), 1.34-1.12 (s, br, 24H, (CH2)12 HD), 0.91 (t, J =  6.44 Hz, 6H, 2*ω-
CH3 Leu), 0.84 (t, J = 7.04 Hz, 3H, ω-CH3 HD). 
 
13C-NMR (125 MHz, CDCl3): 
δ = 172.15, 171.40, 171.19, 168.64, 163.66 (5*C=O), 59.80 (α-CH Pro), 54.10, 54.42 
(α-CH Met, α-CH Cys), 52.18 (OCH3), 48.79 (α-CH Leu), 47.47 (δ-CH Pro), 42.82 
(α-CH2 Gly), 42.82 (β-CH2 Leu), 42.79 (β-CH2 Cys), 41.78, 33.58, 33.52, 32.32, 
31.87, 30.46, 29.63, 29.61, 29.57, 29.50, 29.46, 29.18 (β-CH2 Met, β-CH2 Pro, γ-CH 
 48
Met, 9* CH2 HD), 24.56 (γ-CH Pro), 23.24 (γ-CH Leu), 22.63 (ω-CH3 Leu), 21.86 
(CH2 HD), 15.28 (SCH3), 14.06 (ω-CH3 HD). 
 
MALDI-TOF m/z: calc: 780.47 [M+Na]+  found: 780.77 




leucyl-L-prolyl-S-hexadecyl-L-cysteine methyl ester 
( Boc-Gly-Cys(Pal)-Met-Gly-Leu-Pro-Cys(HD)-OMe ) (48) 
EDC (17 mg, 87 µmol), triethylamine (9.3 µl, 67 µmol) and HOBt (15 mg, 0.101 
mmol) were added to a cooled, stirring solution of H-Met-Gly-Leu-Pro-Cys(HD)-
OMe (51 mg, 67 µmol) and Cys(HD)-OMe (35 mg, 67 µmol). The reaction was 
brought up to room temperature overnight.  After 18h, the reaction organic phase was 
extracted two times each with 1N HCl, sat. NaHCO3, brine followed by drying over 
Na2SO4.  The crude oil was purified by flash chromatography in straight ethyl acetate. 
 
Yield: 48 mg (57%) 
Rf value: 0.16 (20:1 ethyl acetate/methanol) 
[α]D20:  -52.3o (c = 1.0, CHCl3) 
 
1H-NMR (400 MHz, CDCl3): 
δ = 4.60-4.64 (m, 2H, 2*α-CH), 4.53 (dd, 3J= 12.32 Hz, 2J= 1.36 Hz, 1H, α-CH2 
Leu), 4.45 (m, 1H, α-CH CysHD), 4.19-4.14 (m, 1H, α-CH Met), 3.99 (d, J = 16.8 Hz, 
1H, α-CH2a Gly), 3.75-3.53 (m, 4H, δ-CH2a Pro, α-CH2b Gly, α-CH2b Gly, δ-CH2a 
Pro), 3.27-3.23 (m, 1H, β-CH2a CysPal), 3.14 (dd, 2J = 13.56 Hz, 3J = 8.44 Hz, 1H, β-
CH2a CysPal), 2.88 (dd, 2J = 13.68 Hz, 3J = 5.48 Hz, 1H, β-CH2a CysHD), 2.78 (dd, 2J = 
13.88 Hz, 3J = 7.04 Hz, β-CH2a CysHD), 2.51-2.41 (m, 6H, α-CH2 Pal, α-CH2, α-CH2 
HD, γ-CH2 Met), 2.20-2.10 (m, 1H, β-CH2a Met), 2.10 (s, 3H, SCH3), 2.05-1.90 (m, 
5H, β-CH2b Met, β-CH2 Pro, γ-CH2 Pro), 1.75-1.61 (m, 2H, γ-CH Leu, β-CH2 Leu), 
1.61-1.52 (m, 2H, β-CH2 Pal), 1.51-1.43 (m, 3H, β-CH2 HD, β-CH2 Leu), 1.37 (s, 9H, 
C(CH3)3), 1.18 (br, 50H, (CH2)12 Pal, (CH2)13 HD), 0.87 (t, 3J = 6.24 Hz, 6H, 2*ω-
CH3 Leu), 0.79 (t, 3J = 7.04, 6H, ω-CH3 Pal, ω-CH3 HD). 
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MALDI-TOF m/z: calc.: 1279.84 [M+Na]+ found: 1279.04 




L-cysteine methyl ester 
( H-Gly-Cys(Pal)-Met-Gly-Leu-Pro-Cys(HD)-OMe ) (33) 
A solution of Boc-Gly-Cys(Pal)-Met-Gly-Leu-Pro-Cys(HD)-OMe (16 mg, 12.7 
µmol) in 2 ml chloroform was cooled to 0oC before adding 5 µl thioanisole and 1 ml 
TFA.  After 10 minutes, the reaction was brought up to room temperature, and left to 
react for another 50 minutes.  The solvents were removed under reduced pressure and 
the remaining TFA was coevaporated two times with toluene.  The crude product was 
purified by flash chromatography in 5:1 DCM/MeOH. 
 
Yield: quantitative. 
Rf value: 0.35 (1:5 MeOH, DCM). 
[α]D20:  -50.3o (c = 1.0, CHCl3). 
 
1H-NMR (400 MHz, CDCl3/MeOH 1:1): 
δ = 4.61-4.68 (m, 2H, 2*α-CH), 4.53 (dd, 3J = 5.9 Hz, 3J = 5.6 Hz, α-CH), 4.43 (dd, 
3J = 6.8 Hz, 3J = 6.7 Hz, 1H, α-CH), 4.14-4.18 (m, 2H, α-CH Met, α-CH2a Gly), 3.85 
(d, 2J = 16.5 Hz, 1H, α-CH2a Gly), 3.81-3.84 (m, 1H, δ-CH2a Pro), 3.76 (s, 3H, 
OCH3), 3.72 (d, 2J = 16.4 Hz, 1H, α-CH Gly), 3.60-3.65 (m, 2H, δ-CH2b Pro, α-CH2b 
Gly), 3.27 (dd, 2J = 14 Hz, 3J = 6.8 Hz, 1H, β-CH2a CysPal), 3.23 (dd, 2J = 14 Hz, 3J = 
6.8 Hz, 1H, β-CH2b CysPal), 3.01 (dd, 2J = 14 Hz, 3J = 5.3 Hz, 1H, β-CH2a CysHD), 
2.90 (dd, 2J = 14 Hz, 3J = 5.3 Hz, 1H, β-CH2b CysHD), 2.60-2.67 (m, 1H, γ-CH2a Met), 
2.61 (t, 3J = 7.8 Hz, 2H, α-CH2 Pal), 2.50-2.60 (m, 3H, γ-CH2 Met, α-CH2 HD), 2.27-
2.35 (m, 1H, γ-CH2 Met), 2.10 (s, 3H, SCH3), 2.01-2.25 (m, 5H, β-CH2 Pro, β-CH2 
Met, γ-CH2 Pro), 1.75-1.90 (m, 2H, β-CH2 Met, γ-CH2 Leu), 1.65-1.70 (m, 2H, β-CH2 
Pal), 1.53-1.59 (m, 2H, β-CH2 HD), 1.46-1.50 (m, 1H, β-CH2 Leu), 1.30 (s, 50H, 
(CH2)12 Pal, (CH2)13 HD), 0.98 (t, 3J = 6.24 Hz, 6H, 2*ω-CH3 Leu), 0.88 (t, 3J = 7.04, 
6H, ω-CH3 Pal, ω-CH3 HD). 
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MALDI-TOF m/z: calc.: 1155.74 [M+H]  found: 1156.79 
   calc.: 1178.74 [M+Na]+ found: 1178.81 
   calc.: 1194.84 [M+K]+ found: 1194.75 
 




Triphenylphosphine (162 mg, 0.618 mmol), dissolved in 1 ml DCM, was added to a 
cooled solution of hexadecyl alcohol (100 mg, 0.412 mmol) and carbon tetrabromide 
(170 mg, 0.515 mmol) in 1 ml DCM.  The reaction was stirred at room temperature 
overnight.  The solvent was removed under reduced pressure, leaving behind a white 
solid.  The crude material was purified with column chromatography (gravity) in 
straight cyclohexane.   
 
Colorless oil. 
Yield: 118 mg (94 %) 
Rf value: 0.77 (1:2 ethyl acetate/cylclohexane) 
 
1H-NMR (400 MHz, CDCl3): 
δ = 3.40 (t, J = 6.8 Hz, 2 H, α-CH2 HD ), 1.85 (m, 2 H, β-CH2 HD), 1.25 (m, 26 H, 
(CH2)13 HD), 0.88 (t, J = 6.4, ω-CH3 HD) 
 
13C-NMR (125 MHz, CDCl3): 
δ = 34.21, 33.08, 32.15, 29.93, 29.92, 29.91, 29.90, 29.89, 29.88, 29.87, 29.86, 29.85, 
29.84, 29.83, 28.77, 29.66, 29.60, 29.59, 29.58, 29.01, 29.00, 28.41, 22.91 (CH2 HD), 






Under slight heating, hexadecyl alcohol (0.5 g, 2.06 mmol) was dissolved in 500 µl 
diethyl ether and 300 µl acetonitrile.  Triphenylphosphine (0.734 g, 2.80 mmol) and 
imidazole (0.182 g, 2.68 mmol) were then added.  The reaction was cooled to 0oC  
before batchwise adding I2 (0.746 g, 2.94 mmol).  The solid reaction was then 
warmed up to room temperature and diluted with 30 ml diethyl ether.  The organic 
phase was washed with a saturated solution of Na2S2O3, brine and then dried over 
Na2SO4.  Gravity chromatography in straight cyclohexane yielded product. 
 
Colorless oil 
Yield:  0.718 g (98 %) 
Rf value: 0.85 (1:2 ethyl acetate/cyclohexane) 
 
1H-NMR (400 MHz, CDCl3): 
δ =3.18 (t, J = 7.04 Hz, 2H, α-CH2 HD), 1.85-1.78 (m, 2H, β-CH2 HD), 1.30-1.20 (m, 
26 H, (CH2)13 HD), 0.88 (t, J = 7.00 Hz, 3H, ω-CH3 HD). 
 
13C-NMR (125 MHz, CDCl3): 
δ =33.58, 31.93, 31.92, 31.91, 30.51, 29.68, 29.66, 29.64, 29.63, 29.61, 29.54, 29.42, 
29.35, 28.54, 26.91, 22.68 (CH2 HD), 14.10 (ω-CH3 HD) 
 
1-hexadecyl-d33- iodide 
( HD-d33-I ) (49) 
1-hexadecyl-d33-ol (50 mg, 0.182 mmol) was dissolved under light heating in freshly 
distilled diethyl ether : acetonitrile 5:3.  Triphenyl phosphine (65 mg, 0.247 mmol) 
and imidazole (19 mg, 0.278 mmol) were then added before cooling the mixture to 
0oC.  Iodine (66 mg, 0.260 mmol) was then added portionwise to the solution and 
brought up to room temperature.  The yellow colored mixture was stirred for an 
additional hour before being diluted with diethyl ether.  The organic phase was 
washed with NaS2O3, then with brine and finally dried over Na2SO4.  The solvent was 
evaporated under reduced pressure and the resulting white crude material was 




Yield:  60 mg  (85%). 
Rf value: 0.85 (1:2 ethyl acetate/cyclohexane) 
 
 
S-Hexadecyl-d33-L-cysteine methyl ester 
( H-Cys(HD-d33)-OMe ) (50) 
Diisopropylethylamine (61 µl, 0.349 mmol) and hexadecyl-d33 iodide (134 mg, 0.349 
mmol) were added to a stirring solution of Cys-OMe.HCl (30 mg, 0.174 mmol) in 
DMF.  After 18 hours, the solvent was removed under reduced pressure.  The 
remaining solid was brought up in diethyl ether and saturated NaHCO3.  The aqueous 
phase was extracted three times with diethyl ether.  The combined organic phases 
were washed with brine and dried over Na2SO4.  The crude oil was further purified by 
flash chromatography in 1:1 ethyl acetate/cyclohexane. 
 
Colorless oil. 
Yield:  38 mg (56%). 
Rf value:  0.26 (1:1 ethyl acetate/cyclohexane). 
 
1H-NMR (400 MHz, CDCl3/MeOH 1:1): 
δ = 3.67 (s, 3H, OCH3), 3.57 (dd, 3J1 = 7.2 Hz, 3J2 = 4.7 Hz, 1H, α-CH Cys), 2.84 (dd, 
3J1 = 13.5 Hz, 3J2 = 4.7 Hz, 1H β-CH2a Cys), 2.69 (dd, 3J1 = 13.5 Hz, 3J2 = 7.4 Hz, 1H 
β-CH2b Cys), 1.68 (s, br, 2H, NH2). 
 
N-tert-butyloxycarbonylglycyl-S-hexadecyl-d33-L-cysteine allyl ester 
( Boc-Gly-Cys(HD-d33)-OAll ) (52) 
DTT (58.3 mg, 378 µmol) and triethylamine (26 µl,  0.189 mmol) were added to a 
degassed solution of (Boc-Gly-Cys-OAll)2 in 5 ml DCM.  After 1.5 hours, the 
reaction was extracted three times with H2O and dried over Na2SO4.  The solvent was 
evaporated under reduced pressure to a colorless oil.  The oil was then dissolved in 5 
ml DMF and cooled to 0oC before adding triethylamine (32 µl, 0.23 mmol) and 
hexadecyl-d33 iodide (113 mg, 0.294 mmol).  After 20 hours, the solvent was 
evaporated under reduced pressure.  The crude product was purified by flash 




Yield:  64 mg (61%). 
Rf value:  0.39 (1:1 ethyl acetate/cycloheaxane) 
 
1H-NMR (400 MHz, CDCl3/MeOH 1:1): 
δ = 6.87 (d, J = 7.4 Hz, 1H, CONH), 5.96-5.86 (m, 1H, CH=CH2), 5.37-5.32 (m, 1H, 
CH=CH2a),  5.29-5.25 (m, 1H, CH=CH2b), 5.14 (s, br, CONH), 4.85-4.81 (m, 1H, α-
CH Cys), 4.66 (t, 3J1 = 1.4 Hz, 1H, OCH2a), 4.65 (t, 3J1 = 1.4 Hz, 1H, OCH2b), 3.91-
3.79 (m, 2H, α-CH2 Gly), 2.98 (dd, 3J1 = 5.3 Hz, 3J2 = 1.0 Hz, 2H, β-CH2 Cys), 1.46 
(s, 9H, C(CH3)3). 
 
13C-NMR (125 MHz, CDCl3): 
δ =  170.27, 169.26 (2 * C=O), 131.29 (CH=CH2), 119.09 (CH=CH2), 66.32 (OCH2), 
51.87 (α-CH Cys), 34.02 (β-CH2 Cys), 28.26 (C(CH3)3). 
 
MALDI-TOF m/z: calc.: 598.57 [M+Na]+ found: 598.85 
   calc.: 614.67 [M+K]+  found: 614.82 
 
N-tert-butyloxycarbonylglycyl-S-palmitoyl-L-cysteine  
( Boc-Gly-Cys(HD-d33)-OH ) (51) 
Boc-Gly-Cys(HD-d33)-OAll (64 mg, 0.11 mmol) and DMB (8.7 mg, 0.055 mmol) 
were dissolved in 100 ml of freshly distilled THF and the solution was degassed.  
After addition of palladium triphenyl phosphine tetrakis (2.5 mg, 2.2 µmol), the 
reaction was stirred in the dark under argon atmosphere for two hours.  The solvent 
was evaporated under reduced pressure, and the crude substance was redissolved in 
DCM.  The organic phase was washed three times with 1M HCl, and then dried over 
Na2SO4.  After evaporation, the crude solid was purified by flash chromatography 
with  1:2 ethyl acetate/cyclohexane. 
 
Yellow oil. 
Yield:  56 mg (93%). 
Rf value:  0.21 (20:1 ethyl acetate/methanol). 
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1H-NMR (400 MHz, CDCl3/MeOH 1:1): 
δ = 4.89-4.72 (m, 1H, α-CH Cys), 3.97 (d, J= 17 Hz, 1H, α-CH2a Gly), 3.80 (d, J= 15 
Hz, 1H, α-CH2b Gly), 3.02-2.98 (m, 2H, β-CH2 Cys), 1.45 (s, 9H, C(CH3)3). 
 




( Boc-Met-Gly-Leu-Pro-Cys(HD-d33)-OMe ) (53a) 
EDC (31 mg, 0.165 mmol), triethylamine (17.7 µl, 0.127 mmol) and HOBt (29 mg, 
0.190 mmol) were added to a cooled, stirring solution of Boc-Met-Gly-Leu-Pro-OH 
(81 mg, 0.127 mmol) and H-Cys(HD-d33)-OMe (50 mg, 0.127 mmol). The reaction 
was brought up to room temperature overnight.  After 18h, the reaction organic phase 
was extracted two times each with 1N HCl, sat. NaHCO3, brine followed by drying 




Yield:  71 mg (63 %). 
Rf value:  0.68 (10:1 ethyl acetate/methanol). 
 
1H-NMR (400 MHz, CDCl3/MeOH 1:1): 
δ =7.75 (d, 2J = 8.8 Hz, 1H, CONH), 7.76 (d, 2J = 7.2 Hz, 1H, CONH), 7.47 (d, 2J = 
9.7 Hz, 1H, CONH), 6.96 (s, 1H, CONH), 5.34-5.26 (m, 1H, α-CH), 4.91-4.86 (m, 
1H, α-CH), 4.71-4.66 (m, 1H, α-CH), 4.37-4.28 (m, 1H, α-CH), 4.11 (d, 2J = 5.0 Hz, 
2H, α-CH2 Gly), 3.76 (s, 3H, OCH3), 3.70-3.64 (m, 1H, δ-CH2b Pro), 2.97 (dd, 3J1 = 
13.9 Hz, 3J2 = 5.2 Hz, 1H, β-CH2a Cys), 2.84 (dd, 3J1 = 13.9 Hz, 3J2 = 6.6 Hz, 1H, β-
CH2b Cys), 2.43-2.34 (m, 2H, γ-CH2 Met), 2.19-2.00 (m, 4H, β-CH2 Met, β-CH2 Pro), 
2.11 (s, 3H, SCH3), 1.98-1.93 (m, 1H, γ-CH2 Pro), 1.74-1.66 (m, 1H, γ-CH2 Leu), 
1.65-1.56 (m, 2H, β-CH2 Leu), 0.99-0.97 (m, 6H, 2 * ω-CH3 Leu). 
 
13C-NMR (125 MHz, CDCl3): 
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δ =  172.12, 171.37, 171.34, 168.52 (4 * C=O), 60.09 (α-CH Pro), 52.68 (α-CH Cys), 
52.46 (α-CH Met), 52.29 (OCH3), 49.09 (α-CH Leu), 48.26 (δ-CH2 Pro), 28.31 
(C(CH3)3), 24.74 (γ-CH2 Pro), 23.49 (γ-CH2 Leu), 22.12 (ω-CH3 Leu), 15.54 (SCH3). 
 
MALDI-TOF m/z: calc.: 913.73 [M+Na]+ found: 914.01 





( H-Met-Gly-Leu-Pro-Cys(HD-d33)-OMe )     (53) 
Peptide 53a was dissolved in 1.5 ml chloroform and cooled to 0oC before adding 
thioanisole and TFA.  The reaction was stirred for 3 hours before first twice 
coevaporating with toluene and then with chloroform, resulting in a coloress oil. 
 
Colorless oil. 
Yield:  60 mg (97%). 
Rf value:  0.03 (10:1 ethyl acetate/methanol). 
 
1H-NMR (400 MHz, CDCl3/MeOH 1:1): 
δ =  4.73-4.66 (m, 1H, α-CH), 4.56-4.36 (m, 1H, α-CH), 4.24-4.19 (m, 1H, α-CH), 
3.79 (s, 3H, OCH3), 3.78-3.62 (m, 4H, α-CH2 Gly, δ-CH2 Pro), 3.10 (dd, 3J1 = 13.1 
Hz, 3J2 = 5.0 Hz, 1H, β-CH2a Cys), 3.01 (dd, 3J1 = 13.5 Hz, 3J2 = 6.5 Hz, 1H, β-CH2b 
Cys), 2.66-2.58 (m, 2H, γ-CH2 Met), 2.24-2.16 (m, 6H, β-CH2 Pro, γ-CH2 Pro, β-CH2 
Met), 2.09 (s, 3H, SCH3), 2.09-2.04 (m, 1H, γ-CH2 Leu), 1.89 (m, 2H, β-CH2 Leu), 
0.90 (m, 6H, 2 * ω-CH3 Leu). 
 
13C-NMR (125 MHz, CDCl3): 
δ =  60.75 (α-CH Pro), 55.46 (α-CH Met), 53.02 (α-CH Cys), 52.79 (OCH3), 50.97 
(α-CH Leu), 50.34 (δ-CH2 Pro), 33.10 (β-CH2 Cys), 29.25 (γ-CH2 Pro), 24.68 (γ-CH2 
Leu), 23.04 (ω-CH3 Leu), 21.05 (ω-CH3 Leu), 15.19 (SCH3). 
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leucyl-L-prolyl-S-hexadecyl-L-cysteine methyl ester 
( Boc-Gly-Cys(HD-d33)-Met-Gly-Leu-Pro-Cys(HD-d33)-OMe ) (54) 
EDC (13 mg, 70.2 µmol), triethylamine (7.5 µl, 54.4 µmol) and HOBt (12.4 mg, 81.6 
µmol) were added to a cooled, stirred solution of H-Met-Gly-Leu-Pro-Cys(HD-d33)-
OMe (43 mg, 54.4 µmol) and Boc-Gly-Cys(HD-d33)-OH (29 mg, 54.4 µmol). The 
reaction was brought up to room temperature overnight.  After 18h, the reaction 
organic phase was extracted two times each with 1N HCl, sat. NaHCO3, brine 
followed by drying over Na2SO4.  The crude oil was purified by flash chromatography 
in 20:1 ethyl acetate/methanol. 
 
Colorless oil. 
Yield:  60% 
Rf value:  0.38 (20:1 ethyl acetate/methanol). 
 
1H-NMR (400 MHz, CDCl3/MeOH 1:1): 
δ =  8.21 (d, 2J = 7.2 Hz, 1H, CONH), 7.85 (d, 2J = 8.6 Hz, 1H, CONH), 7.64 (d, 2J = 
6.4 Hz, 1H, CONH), 7.55 (d, 2J = 8.02 Hz, 1H, CONH), 7.35 (d, 2J = 8.4 Hz, 1H, 
CONH), 4.52-4.46 (m, 1H, α-CH), 4.44-4.42 (m, 1H, α-CH), 4.35-4.32 (m, 1H, α-
CH), 4.29-4.24 (m, 1H, α-CH), 4.04-3.98 (m, 2H, α-CH2 Gly), 3.94-3.92 (δ-CH2 
Pro)3.90-3.88 (m, 2H, α-CH2 Gly), 3.53 (s, 3H, OCH3), 2.74 (dd, 3J1 = 13.9 Hz, 3J2 = 
5.5 Hz, 2H, β-CH2 Cys), 2.68-2.56 ( m, 1H, γ-CH2 Met), 2.42-2.30 (m, 1H, γ-CH2), 
2.08-2.02 (m, 1H, β-CH2a Met), 1.95-1.80 (m, 5H, β-CH2b Met, β-CH2 Pro, γ-CH2 
Pro), 1.44-1.33 (m, 1H, β-CH2b Leu), 1.22 (s, 9H, C(CH3)3), 0.72 (m, 6H, 2 * ω-CH3 
Leu). 
 
MALDI-TOF m/z: calc.: 1331.22 [M+Na]+ found: 1331.15 




hexadecyl-d33-L-cysteine methyl ester 
( H-Gly-Cys(HD-d33)-Met-Gly-Leu-Pro-Cys(HD-d33)-OMe ) (34) 
A solution of Boc-Gly-Cys(HD-d33)-Met-Gly-Leu-Pro-Cys(HD-d33)-OMe (17 mg, 
12.9 µmol) in 1.5 ml chloroform was cooled to 0oC before adding 7.6 µl thioanisole 
and 0.5 ml TFA.  After 10 minutes, the reaction was brought up to room temperature, 
and left to react for another 2 hours.  The solvents were removed under reduced 
pressure and the remaining TFA was twice coevaporated with toluene.   
 
Yellow oil. 
Yield: 15mg (96%). 
Rf value: 
 
1H-NMR (400 MHz, CDCl3/MeOH 1:1): 
δ =  8.51 (d, 2J = 6.8 Hz, 1H, CONH), 7.82 (d, 2J = 5.2 Hz, 1H, CONH), 7.41 (d, 2J = 
7.4 Hz, 1H, CONH), 4.37-4.34 (m, 1H, α-CH), 4.27-4.24 (m, 2H, α-CH), 4.13-4.09 
(m, 1H, α-CH), 3.96-3.90 (m, 1H, α-CH), 3.66-3.59 (m, 2H, α-CH2 Gly), 3.56-3.44 
(m, 3H, δ-CH2a Pro, α-CH2 Gly), 3.40-3.32 (m, 1H, δ-CH2b Pro), 2.95-2.76 (m, 2H, γ-
CH2 Met), 2.76-2.66 (m, 2H, β-CH2 Cys), 2.65 (m, 2H, β-CH2 Cys), 2.45 (m, 1H, β-
CH2b Met), 2.10-2.04 (m, 1H, β-CH2 Cys), 1.96-1.78 (m, 5H, β-CH2b Met, β-CH2 Pro, 
γ-CH2 Pro), 1.63-1.53 (m, 2H, γ-CH2 Leu, β-CH2a Leu), 1.46-1.20 (m, 1H, β-CH2b 
Leu), 0.71-0.68 (m, 6H,2 * ω-CH3 Leu). 
 
 
MALDI-TOF m/z: calc.: 1231.16 [M+Na]+ found: 1231.47 




Appendix A:  Abbreviations. 
 
GPI glycoinositol phospholipid 
GTP guanosine triphosphate 
GDP guanosine diphosphate 
EEDQ 2-ethoxy-1-ethoxycarbonyl-1,2-dihydrochinoline 
DCC N, N´-dicyclohexylcarboiimide 






HBTU 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
HATU O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
HOBt N-hydroxybenzotriazole.H2O 
HOAt 1-hydroxy-7-azabenzotriazole 
Fmoc 9-fluorenylmethoxy carbonyl 
Boc tert-butyloxy carbonyl 





NMR nuclear magnetic resonnance 
TIS triisopropyl silane 
TFA trifluoroacetic acid 





DMF N, N-dimethyl formamide 
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DMB N,N-dimethyl barbituric acid 
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